Atara Biotherapeutics, Inc. (ATRA) stock

ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30

$7.70−0.23 (-2.90%)

Close on Nov 13, 2026Market cap $77.29MP/E –Yield –

Atara Biotherapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Atara Biotherapeutics's price to sales ratio was 12.5× on Nov 11, 2026, against 0.7× a year earlier. Over the last 4 years it ranged from 0.2× to 21.8×, with a median of 1.9×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	12.5×	+11.7
2025	Dec 31, 2025	0.9×	+0.1
2024	Dec 31, 2024	0.8×	−10.7
2023	Dec 29, 2023	11.5×	–

Where these numbers come from

Parsed from the XBRL in Atara Biotherapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-25 reverse split on Jun 20, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing